Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
11 Gennaio 2024 - 2:30PM
Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a
clinical-stage biopharmaceutical company focused on translating
today’s medical breakthroughs in cell and gene therapies into
potential cures for difficult-to-treat cancers and rare genetic
diseases, today announced that Manuel Litchman, M.D., President and
Chief Executive Officer, will participate in a fireside chat at the
B. Riley Securities 4th Annual Oncology Conference, taking place on
Thursday, January 18, 2024, at 4:30 p.m. EST.
To access this event, please RSVP to your B.
Riley Securities sales representative. A replay of Mustang’s
fireside chat will be available on this link after the meeting.
About Mustang BioMustang Bio,
Inc. is a clinical-stage biopharmaceutical company focused on
translating today’s medical breakthroughs in cell and gene
therapies into potential cures for difficult-to-treat cancers and
rare genetic diseases. Mustang aims to acquire rights to these
technologies by licensing or otherwise acquiring an ownership
interest, to fund research and development, and to outlicense or
bring the technologies to market. Mustang has partnered with top
medical institutions to advance the development of CAR-T therapies
across multiple cancers, as well as lentiviral gene therapies for
severe combined immunodeficiency. Mustang’s common stock is
registered under the Securities Exchange Act of 1934, as amended,
and Mustang files periodic reports with the U.S. Securities and
Exchange Commission (“SEC”). Mustang was founded by Fortress
Biotech, Inc. (Nasdaq: FBIO). For more information, visit
www.mustangbio.com.
Company Contacts:Jaclyn Jaffe and Nicole
McCloskeyMustang Bio, Inc.(781) 652-4500ir@mustangbio.com
Grafico Azioni Mustang Bio (NASDAQ:MBIO)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mustang Bio (NASDAQ:MBIO)
Storico
Da Dic 2023 a Dic 2024